Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 17/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5162217 | 1.00 | TACR1 (0.49) | TACR1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5162654 | 1.00 | TACR1 (0.49) | TACR1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5159633 | 0.81 | TACR1 (0.49) | TACR1 | |
| SCHEMBL5159352 | 0.81 | TACR1 (0.49) | TACR1 | |
| SCHEMBL9024291 | 0.74 | TACR1 (0.54) | TACR1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5269321 | 0.73 | TACR1 (0.51) | TACR1TP53CYP1A2CYP3A4CYP2D6 | |
| Oxalic Acid SCHEMBL9024728 | 0.70 | TACR1 (0.49) | TACR1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5161762 | 0.67 | TACR1 (0.58) | TACR1CYP3A4 | |
| SCHEMBL9544307 | 0.67 | TACR1 (0.46) | TACR1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL14446232 | 0.65 | POLB (0.36) | TACR1TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241798-B2 | NK1 antagonists | PFIZER INC. (US) | 2007-07-10 | — | — | US | claimed |
| US-20050272800-A1 | NK1 antagonists | PFIZER INC | 2005-12-08 | — | — | US | claimed |
| US-7241798-B2 | NK1 antagonists | PFIZER INC. (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1756056-A1 | AZA-BICYCLO[3.1.0]HEX-1-YL DERIVATIVES ACTIVE AS NK1 ANTAGONISTS | Pfizer Products Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005121085-A1 | AZA-BICYCLO`3.1.0!HEX-1-YL DERIVATIVES ACTIVE AS NK1 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050272800-A1 | NK1 antagonists | PFIZER INC | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272800-A1 | NK1 antagonists | TACR1, TACR2, TAC3 | TACR1 1/4885TP53 4496/4885CYP1A2 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.